Literature DB >> 15743360

Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.

Alex Yui Hui1, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Choong-Tsek Liew, Angel Mei-Ling Chim, Francis Ka-Leung Chan, Joseph Jao-Yiu Sung.   

Abstract

OBJECTIVE: Histological assessment of liver fibrosis is important in the management of chronic hepatitis B (CHB) infection but poorly accepted by patients because of its invasiveness. The aim of this study was to develop a noninvasive model to assess liver fibrosis in CHB patients using clinical and routine laboratory data. PATIENTS AND METHODS: This was a retrospective study on 235 treatment-naive viremic CHB patients. Univariate analysis of data from the training cohort (n = 150) followed by multivariate logistic regression were performed to identify independent predictors of significant fibrosis and generate predictive models. The models were validated with the remaining patients or validation cohort (n = 85) and by receiver operating characteristics (ROC) analysis.
RESULTS: Body mass index (BMI), platelet count, serum albumin, and total bilirubin levels were identified as independent predictors of bridging fibrosis or cirrhosis (Ishak stage 3-6). ROC analysis was performed using the predictive probabilities derived from the regression models. The area under the ROC curve of the best model was 0.803 (95% CI: 0.729-0.878) for the training cohort, 0.765 (95% CI: 0.644-0.885) for the validation cohort, and 0.791 (95% CI: 0.728-0.854) for the entire cohort. Using the low cut-off probability of 0.15, significant fibrosis could be excluded in 83 patients of the total patient population (negative predictive value 0.92).
CONCLUSIONS: Our noninvasive model comprising BMI and three routine laboratory tests was accurate in predicting absence of significant fibrosis. Application of this model could provide useful additional information on the stage of disease, guide future management decisions, and potentially decrease the need for liver biopsy in some CHB patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15743360     DOI: 10.1111/j.1572-0241.2005.41289.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  51 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

Review 2.  An appraisal of the histopathological assessment of liver fibrosis.

Authors:  R A Standish; E Cholongitas; A Dhillon; A K Burroughs; A P Dhillon
Journal:  Gut       Date:  2006-04       Impact factor: 23.059

Review 3.  Liver elastography, comments on EFSUMB elastography guidelines 2013.

Authors:  Xin-Wu Cui; Mireen Friedrich-Rust; Chiara De Molo; Andre Ignee; Dagmar Schreiber-Dietrich; Christoph F Dietrich
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

4.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

5.  Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B?

Authors:  Murat Kekilli; Alpaslan Tanoglu; Yusuf Serdar Sakin; Mevlut Kurt; Serkan Ocal; Sait Bagci
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 6.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

7.  Serum hyaluronic acid: a promising marker of hepatic fibrosis in chronic hepatitis B.

Authors:  Gamal Shiha
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

8.  Identification of the risk for liver fibrosis on CHB patients using an artificial neural network based on routine and serum markers.

Authors:  Danan Wang; Qinghui Wang; Fengping Shan; Beixing Liu; Changlong Lu
Journal:  BMC Infect Dis       Date:  2010-08-24       Impact factor: 3.090

9.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

10.  Transient elastography: Kill two birds with one stone?

Authors:  Grace Lai-Hung Wong
Journal:  World J Hepatol       Date:  2013-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.